Author:
Lin Shengchao,Zhang Yu,Yao Jun,Yang Junjie,Qiu Yang,Zhu Zhongyuan,Hua Haiqing
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Cancer.Net. Lung Cancer - Small Cell: Statistics. 2/27. 2023. Accessed 2/27, 2023. https://www.cancer.net/cancer-types/lung-cancer-small-cell/statistics
2. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D’Amico TA, et al. Small cell Lung Cancer, Version 2.2022, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:1441–64.
3. Society AC. Lung Cancer Survival Rates|5-Year Survival Rates for Lung Cancer. https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival-rates.html
4. Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51–65.
5. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with atezolizumab, carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021;39:619–30.